🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are escalating globally, with data suggesting more than 82 million new cases each year. Particularly high rates are seen in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the reality of growing infection rates, the spread of superbugs and the very limited available drugs currently available.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in the same week. This medication, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on data detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The research involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Medical professionals directly involved have voiced positive views. Having a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to reduce the burden of the infection for individuals and to prevent the spread of untreatable gonorrhoea around the world.